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 Abstract.  We evaluated the cost-effectiveness of distributing insecticide-treated bed nets (ITNs) for malaria preven-
tion at antenatal clinics in Kinshasa, Democratic Republic of the Congo. A decision tree model was used to estimate costs, 
outcomes, and incremental cost-effectiveness for 17,893 pregnant women attending 28 antenatal clinics who received 
long-lasting ITNs free of charge. Costs including purchase, transportation, storage, and distribution of ITNs were derived 
from program records. The ITN efficacy and other parameters were derived from peer-reviewed literature. Outcomes 
modeled included low birth weight (LBW) deliveries, infant deaths averted, life-years saved (LYs), and disability-adjusted 
life-years (DALYs) averted. Deterministic and probabilistic sensitivity analyses were conducted. For the 17,893 women 
in our program, ITN distribution would be expected to avert 587 LBW deliveries and 414 infant deaths. The incremental 
cost-effectiveness was US $17.22 per DALY averted (95% confidence interval [CI] = US $8.54–$30.90), US $15.70 per 
LY saved (95% CI = US $7.65–$27.68), and US $411.13 per infant death averted (95% CI = US $353.95–$1,085.89). If 
resources were constrained, the greatest benefit would be among women in their first through fourth pregnancies. Thus, 
ITN distribution is a cost-effective addition to antenatal services. 
 INTRODUCTION 
 Use of insecticide-treated bed nets (ITNs) can effectively 
prevent malaria. Their use by pregnant women reduces the 
incidence of low birth weight (LBW) by 23% in first through 
fourth pregnancies, and use by children reduces all-cause mor-
tality by 17%. 1,2 The protective effect observed in children is 
strongest during the first year of life. 3 Because infants in sub-
Saharan Africa typically sleep with their mothers, distribution 
of ITNs at the antenatal clinic benefits pregnant mothers and 
subsequently their infants. 
 The World Health Organization recommends that preg-
nant women and children less than five years of age in sub-
Saharan Africa should have the highest priority for receiving 
ITNs. 4 However, possession of ITNs in sub-Saharan Africa 
remains low, with only 6.7% of households owning one. 5 The 
antenatal clinic is a logical target for ITN distribution because 
70% of women in sub-Saharan Africa will visit the antenatal 
clinic during their pregnancies. 6 Also, integrating programs 
and using existing infrastructure can contain costs, an impor-
tant objective in resource-poor countries that must choose 
between many needed interventions. 
 In this context, we estimated the programmatic costs, ben-
efits, and the cost-effectiveness of adding ITN distribution at 
antenatal clinics from the health provider perspective. During 
November 2005–September 2006, we assisted 28 antena-
tal clinics in Kinshasa, Democratic Republic of the Congo 
(DRC), with the implementation of a prevention of maternal-
to-child transmission (PMTCT) of human immunodeficiency 
virus (HIV) program. As part of these PMTCT activities, 
17,893 women were given long-lasting ITNs free of charge. 
Malaria is common among pregnant women in Kinshasa; 60% 
of women at a Kinshasa maternity hospital had a positive 
malaria smear during pregnancy at the time our intervention 
was conducted. 7 
 We determined the cost-effectiveness of adding ITN distri-
bution using the actual costs of this intervention derived from 
program records. Using a decision model, we modeled the esti-
mated infant deaths and LBW deliveries averted by ITN use, 
using data from published studies of ITN efficacy. 1,2 
 MATERIALS AND METHODS 
 Program site.  Distribution of ITNs was conducted at 28 
antenatal clinics providing PMTCT services in Kinshasa. 
These antenatal clinics are managed by the DRC Ministry 
of Health or by non-governmental organizations, mainly 
religious organizations. A total of 26–320 new antenatal patients 
attended the clinics per month, which resulted in a total of 
33,541 patients during the course of the intervention. Prior 
to the intervention, none of the clinics distributed bed nets. 
In addition to PMTCT services with single-dose nevirapine, 
the clinics provide a minimum antenatal package including 
malaria diagnosis and treatment, intermittent preventive 
treatment of malaria in pregnancy (IPTp), iron and folate 
supplementation, nutrition counseling, syphilis diagnosis 
and treatment, tuberculosis diagnosis and treatment, tetanus 
immunizations, and family planning counseling. 
 Intervention.  We distributed 17,893 long-lasting ITNs free 
of charge to pregnant women attending antenatal clinics 
providing PMTCT services in Kinshasa. During November 
2005–September 2006, the implementation of the program 
occurred in a step-wise manner as clinic staff received training 
and the ITNs became available for distribution. Two nurses per 
site received five days of comprehensive malaria education prior 
to distribution. Nurses then distributed ITNs during antenatal 
educational sessions, providing information on correct ITN 
use and malaria transmission. Of 33,541 women who received 
antenatal care during this period, only 17,893 women received 
ITNs because the program was phased in as sites received 
training and ITNs for distribution. Also, a change in the funding 
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arrangements made the ITNs unavailable for a short time at all 
sites. Finally, ITNs were not distributed if both trained nurses at 
a site were absent from work. Women who missed distribution 
at their first visit may have received an ITN at a subsequent visit 
if trained staff and ITNs were available. However, if women did 
not return for additional visits, they did not receive an ITN. 
 We used long-lasting insecticide-treated nets (Permanet ® 
2.0; Vestergaard-Frandsen, Lausanne, Switzerland) donated 
by the Global Fund and the U.S. Centers for Disease Control 
and Prevention. Long-lasting ITNs maintain efficacy with-
out insecticide re-treatment for up to 20 washes. 8 Because 
bed nets are generally washed infrequently, these long-lasting 
ITNs would maintain efficacy when used during pregnancy 
and one year postpartum. 
 Ethical clearance.  This study was reviewed and approved by 
the Biomedical Institutional Review Board of the Office of 
Human Research Ethics at the University of North Carolina 
at Chapel Hill. 
 Description of model and parameters.  Using a decision tree 
model, we estimated the number of LBW deliveries and infant 
deaths averted, life-years (LYs) saved, and disability-adjusted 
life-years (DALYs) averted for the cohort who received ITNs 
to use during their pregnancies and for their infants after 
birth. The model takes the health care provider perspective 
and uses a time horizon that runs from the receipt of the 
ITNs to one year postpartum. We then simulated disability-
adjusted life expectancy for the infants. Model parameters and 
corresponding data sources are summarized in Table 1 9–24 and 
are described below. 
 We modeled the outcomes for the entire cohort of 17,893 
women. Women were offered HIV testing and nevirapine as 
indicated by the standard PMTCT protocol. The HIV preva-
lence among women attending the clinics was 2.2% (range = 
0.3–5.5%), which was similar to other estimates of HIV sero-
prevalence in Kinshasa. 25 
 Standard practice in Kinshasa is to provide IPTp for malaria 
with two doses of sulfadoxine-pyrimethamine to all pregnant 
women, with a third dose for HIV-positive women. Clinic-
level data on the number of women receiving each dose were 
used; the base-case likelihood was estimated to be the mean 
for all of the clinics (78.3% for the first dose and 50.9% for 
the second dose), with the range across clinics used in sensi-
tivity analyses. Because data were not available by HIV sta-
tus, we estimated the compliance with the third dose among 
HIV-positive women as the number of women receiving third 
doses divided by the number of HIV-positive women seen by 
the clinic: 39.4% received all three doses of IPTp (range 0% 
[4 clinics] to 100% [4 clinics]). 
 Women could choose to use the ITN provided during preg-
nancy and during the infant’s first year of life. Questionnaires 
were used to measure adherence with ITN use among the 
women attending the Bomoi Antenatal Clinic in the N’Djili 
 T able 1 
Base-case and range of inputs for model parameters* 
Parameters Base-case value (range†) Data source
Mother HIV-positive 2.1% (0.3–5.5%) 28 ANCs
Infant mortality rate (per 1,000) 95 (83–129)  9–11 
RR (LBW vs. not LBW) 3.08 (95% CI = 1.51–6.23)  12 
RR (maternal HIV+ vs. HIV−) 3.44 (95% CI = 1.63–7.26)  12 
RR (infant ITN vs. no ITN) 0.78 (95% CI = 0.67–0.90)  3 
Low birth weight rate (per 1,000) 120 (92–164) Bomoi 13,14 
RR (maternal HIV+ vs. HIV−) 2.29 (95% CI = 1.34–3.92)  15 
RR (maternal ITN vs. no ITN) 0.72 (95% CI = 0.53–0.98)  16 
Stillbirth rate (per 1,000) 56 (42–70) Bomoi ANC 17 
RR (maternal HIV+ vs. HIV−) 2.7 (95% CI = 1.3–5.5)  18 
RR (maternal ITN vs. no ITN) (first–fourth pregnancy)‡ 0.67 (95% CI = 0.47–0.97)  1 
HIV transmission to infant by one year of life
Mother did not receive nevirapine 25.7 (95% CI = 18.8–32.5)  19 
Mother received nevirapine 15.3% (±10%)  20 
Adherence to ITN by
Mother 85% (±10%) Bomoi ANC
Infant 63% (±10%) Bomoi ANC
Adherence to IPTp
First dose (HIV+/HIV−) 78% (25–100%) 28 ANCs
Second dose (HIV+/HIV−) 51% (2–100%) 28 ANCs
Third dose (HIV+ only) 39% (0–100%) 28 ANCs
PMTCT received 55% (±10%) 28 ANCs
Outcomes
Time with HIV (in months) 13.9  21 
Time with AIDS (in months) 9 (4–21)  21 
Disability weight (HIV) 0.123  22 
Disability weight (AIDS) 0.505  22 
Life expectancy at age 1 (in years) 49.8  23 
Costs per ITN (in 2005 US $)
ITN purchase and transport to Kinshasa $8.00 ($6.01–$8.00) Program
Storage and security $0.22 Program
Transport to clinics $0.84 Program
Training for providers $0.44 Program
Distribution within clinic $0.011 ($0.003–$0.019) Program
 *  Rates were transformed to risks using risk = 1 − e −(rate)×(time)24 . HIV = human immunodeficiency virus; ANC = antenatal clinic; RR = relative risk; LBW = low birth weight delivery; CI = confi-
dence interval; ITN = insecticide-treated bed net; IPTp = intermittent preventive treatment (pregnancy); PMTCT = prevention of mother-to-child transmission of HIV; AIDS = acquired immuno-
deficiency syndrome; Program = program records. 
 †  Ranges derived from available 95% CIs, multiple studies, or minimum/maximum of clinic data). 
 ‡  For women of parity 1–2 who do not receive a full course (i.e., two doses for HIV− women and 3 doses for HIV+ women) of IPTp and who use ITNs; otherwise used for women of parity 3–4 
who used ITNs. 
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Health Zone. Bomoi Antenatal Clinic, administered by the 
Salvation Army, is the largest clinic, attending an average of 
320 new pregnant patients each month. A baseline question-
naire was administered to 360 women chosen randomly from 
the first 1,000 women who received ITNs. A second question-
naire was administered in the postpartum ward at delivery (32 
women were lost to follow-up) and a third questionnaire was 
administered during a home visit 6 months postpartum to 103 
women chosen randomly from the initial 360 women. At the 
time of delivery and at 6 months postpartum, 85% and 84% 
of women, respectively, responded that they slept under the 
bed net everyday or almost everyday during the past month. 
At 6 months postpartum, 63% of women reported that the 
child slept under the ITN the previous night. Interviewers also 
observed that 70% of households had the ITN hanging in the 
correct position during the home visit. Women in the study 
washed the nets a maximum of eight times. 
 Health outcomes.  Stillbirths and LBW infants averted.  We 
used the stillbirth rate among women attending the Bomoi 
Antenatal Clinic (5.6%) as the base-case, or most likely, 
scenario. The minimum value was derived from 2001 data for 
the DRC. 15 Because we used stillbirth rates from Kinshasa, 
where IPTp is considered standard of care, we did not adjust 
the stillbirth rates for IPTp use. We did adjust the stillbirth 
rate up or down depending on the mother’s HIV status using 
data from Kenya. 18 In addition, we adjusted for the effect of 
ITN use during pregnancy for women in their first and second 
pregnancies who did not receive a full course of IPTp. 16 Because 
women in their third and fourth pregnancies who used their 
ITNs were assumed to receive benefits from the ITNs but not 
IPTp, 26 we adjusted their stillbirth rate. For women of parity 
greater than 4, we assumed no benefit from the ITNs, 1 but did 
assume a protective effect for their live-born infants. 
 The base-case rate for LBW (i.e., birth weight < 2,500 g) was 
that rate reported by the United Nations Children’s Fund for 
the DRC. 13 For the minimum and maximum rates, we used the 
rates among women attending the Bomoi Antenatal Clinic and 
for Maniema, DRC, 14 respectively. Because numerous studies 
have shown that the prevalence of LBW is higher in infants 
born to HIV-positive mothers, 15,27,28 we adjusted the rates of 
LBW up or down depending on the mother’s HIV status. As 
we had done for stillbirth rates, we adjusted the LBW rates 
for ITN use in the following way. For women of first or second 
parity who did not receive a full course of IPTp but used the 
ITN during pregnancy, we accounted for the protective effect 
of the ITN; women (first or second parity only) who received 
a full course of IPTp and used their ITNs did not receive any 
additional protection from the ITN. 
 Infant deaths averted.  As the base-case, we used the infant 
mortality rate of 95 per 1,000 for urban DRC, 9 with minimum 
and maximum values corresponding to the rates for Kinshasa 10 
and all of the DRC, 11 respectively. The infant mortality rate 
was adjusted to reflect the protective efficacy of ITN use dur-
ing the first year of life 3 and to account for increased risks of 
infant mortality associated with LBW and HIV status using 
data from Malawi. 12 The protective efficacy of ITN use was 
based on an efficacy study in Kenya, 3 which also has perennial 
malaria transmission. 
 Life-years and disability-adjusted life-years .  The HIV-
negative children who survived the first year of life were 
assumed to survive an additional 49.8 years, the life expectancy 
at ages 1–4 in the DRC. 23 The HIV-positive children who sur-
vived beyond the first year of life were assumed to survive 22.9 
months. 21 We combined life expectancy with health state valu-
ations (i.e., weights associated with illnesses and conditions) 
to calculate DALYs. Age-specific health state valuations from 
the World Health Organization’s Choosing Interventions that 
are Cost Effective (CHOICE program) 29 were combined with 
life expectancy for HIV-negative children. For children with 
HIV and/or acquired immunodefiency syndrome, health state 
valuations were calculated as one minus the disability weight 
associated with a particular health state. 22 
 Costs.  We used a health provider perspective, estimating 
the cost of ITN distribution using program records. Costs 
include the cost of the ITNs, transport of ITNs to Kinshasa, 
storage of ITNs, transportation of ITNs within Kinshasa, staff 
training, and staff wages for distribution ( Table 1 ). All costs 
are expressed in 2005 US dollars. The Global Fund donated 
the ITNs at $8 each, inclusive of shipping and customs; in 
sensitivity analysis, we used estimates obtained directly from 
the manufacturer (US $6.01). Clinic administrators provided 
wages for staff ranging from US $0.174 to US $1.15 per hour. 
These wages for persons involved in the program include 
salary and benefits. Health care costs (i.e., medications, clinic 
visits, and hospitalizations) averted by the intervention were 
not included in the model, nor were changes in total health 
care costs because of survival of infants. 
 Analyses.  Cumulative costs, numbers of infant deaths, 
LYs, and DALYs were estimated with and without the ITN 
program. The difference in cost was divided by the difference 
in outcomes to calculate the incremental cost-effectiveness 
ratios (ICERs) in US dollars per infant death averted, LY 
saved, and DALY averted. Costs and outcomes occurring 
beyond the first year were discounted to the beginning of the 
model at 3% per year. 30,31 The primary or base-case analysis 
was performed for all women. 
 We conducted both one-way and probabilistic sensitivity 
analyses to account for differences at the 28 antenatal clinics 
and in the data used in the decision model. 30,32,33 One-way (deter-
ministic) sensitivity analyses were used to assess the robustness 
of our findings to variations in individual model parameters. 
To do this assessment, we varied key model parameters across 
plausible values one at a time and examined the corresponding 
effects on the ICERs. Simulations also were performed to esti-
mate outcomes and cost-effectiveness ratios for two additional 
distribution schemes: 1) women of first or second parity only 
(i.e., a situation of extreme resource constraints) and 2) women 
of first through fourth parity (i.e., resource constraints less dire 
than under the first scenario). In these scenarios, we would have 
distributed ITNs to 9,483 and 14,851 women, respectively, and 
thus apportioned the costs of ITN transport, security, and stor-
age; staff training; and distribution costs across these reduced 
number of ITNs. That is, cost per ITN for women of first or sec-
ond parity only and first through fourth parity only were US 
$10.87 and US $9.83, respectively. 
 To assess parameter uncertainty, probabilistic sensitivity 
analyses were conducted using Monte Carlo simulation (2,000 
iterations). All simulations were conducted using Crystal Ball 
version 7.3.1 (Decisioneering, Oracle, Denver, CO). Risks or 
probabilities were modeled using beta distributions and rel-
ative risks with the lognormal distribution. 34 Where ranges 
of input values (e.g., 95% CIs or multiple sources of data) 
were unavailable from the literature or program records, we 
assigned plausible ranges of ±10% of the base-case values. 
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 Results of these simulations are depicted in an incremen-
tal cost-effectiveness plane that demonstrates the likelihood 
that adding ITNs is cost-effective for values that a decision 
maker would be willing to pay to avoid an additional DALY. 
Typically, any intervention with an ICER less than the per cap-
ita gross domestic product (GDP) per DALY averted (in the 
case of the DRC, US $700/DALY averted) would be consid-
ered highly cost-effective. Interventions having ICERs above 
that level but less than three times the GDP per capita/DALY 
were considered worthwhile or cost-effective. 31 However, it is 
reasonable to argue that a low- or middle resource country 
might not consider spending that much for a medical interven-
tion given competing priorities. Thus, we often compare our 
ICERs to a lower threshold, the per capita health care expen-
diture (i.e., in the DRC, US $15/DALY averted 35 ), under the 
assumption that doing so is more likely to place the interven-
tion into an appropriate context. In the analyses presented 
here, we compare our results to both thresholds. 
 RESULTS 
 Adding ITN distribution at 28 antenatal clinics in Kinshasa 
is estimated to have yielded 414 fewer infant deaths (2,165 
versus 1,751) and 587 fewer LBW deliveries (3,140 versus 
3,727), save 10,855 life-years, and avert 9,897 DALYs com-
pared with the standard antenatal services ( Table 2 ). The addi-
tional costs of the program were estimated to be US $170,423, 
or US $9.52 per ITN distributed. The cost-effectiveness ratios 
for our base-case scenario were US $411.13 per infant death 
prevented, US $15.70 per LY saved, and US $17.22 per DALY 
averted. Of the infant deaths averted, 247 were among women 
carrying their first or second pregnancy, 149 were among 
women carrying their third or fourth pregnancy, and 18 were 
among women carrying their fifth or greater pregnancy. The 
distribution of parities in our study was 53% first or second 
pregnancy, 30% third or fourth pregnancy, or 17% fifth or 
greater pregnancy. 
 Our simulations of different distribution schemes ( Table 2 ), 
despite increased costs per ITN, remained highly cost-effective 
compared with the commonly accepted threshold of one times 
the GDP per DALY averted (i.e., US $700/DALY averted) and 
was just slightly higher than our proposed lower threshold of the 
per capita health expenditures (US $15/DALY averted). Finally, 
because malaria parasitemia is so high in Kinshasa despite use 
of IPTp 7 (60% of women were positive during pregnancy), we 
modeled a scenario in which women of first or second par-
ity who received a full IPTp course and used their ITNs dur-
ing pregnancy had reduced stillbirth and LBW rates as a result 
of using the ITN. The incremental cost-effectiveness ratio con-
tinued to be highly cost-effective at US $16.93/DALY averted 
(compared with a base-case of US $17.22/DALY). 
 Results of probabilistic analyses are plotted in the incre-
mental cost-effectiveness plane ( Figure 1 ). All points lie in 
the quadrant where providing ITNs is more costly and more 
effective. All 1,000 points lie to the right and below the $700/
DALY averted threshold, thus suggesting that adding ITNs 
would be considered highly cost-effective. 31 The dashed line 
indicates the threshold ICER of $15/DALY (the per capita 
health care expenditure in the DRC); 492 of the 1,000 simu-
lation results lie below or to the right, suggesting that adding 
ITNs would be cost-effective at this reduced threshold. The 
cost-effectiveness acceptability curve ( Figure 2 ) indicates 
that there is a 49.2% likelihood that providing ITNs to all 
women regardless of parity is cost-effective at a threshold 
of US $15.00/DALY. At US $36.02/DALY, a decision maker 
would have a 1% chance of making the wrong decision by 
adding ITNs; at US $106/DALY, adding ITNs is always cost-
effective. 
 Systematic variation of individual model parameters in one-
way sensitivity analyses ( Table 3 ) indicates that the model is 
most sensitive to variations in the relative risks of stillbirth 
and infant mortality associated with ITN use, the relative risk 
of infant mortality associated with LBW, the incidence rates of 
stillbirths and infant mortality, and the cost of the ITNs. The 
results of the one-way sensitivity analyses were similar regard-
less of outcome measure examined. Purchasing ITNs directly 
from the manufacturer improved the cost-effectiveness to 
US $13.62/DALY averted, US $325.23/death averted, and US 
$12.42 per life-year saved. 
 DISCUSSION 
 Distribution of ITNs at 28 antenatal clinics in Kinshasa 
prevented an estimated 414 infant deaths. From the health 
provider perspective, it costs US $411.13 per infant death 
prevented, US $15.70 per life-year saved, and US $17.22 per 
DALY averted. Our results are more favorable than results 
previously reported for ITN distribution through a social 
marketing program (US $873 per child death averted) 36 and 
compare favorably with distribution alongside a measles vac-
cination program (US $635 per child death averted, US $16 
per DALY averted). 37 Our results also compare favorably with 
other preventive measures, for example, U.S. $84 per DALY 
averted for PMTCT with nevirapine, 38 US $2 to US $17 per 
DALY averted for measles vaccination, 39 and more than US 
$2,000 per DALY averted for hypertension management. 39 
 Distribution at the antenatal clinic benefits not only the 
pregnant woman, but also the infant, because of use by the 
mother-infant pair after delivery. Also, distribution alongside 
PMTCT services facilitates ITN access for HIV-positive preg-
nant women, who have greater morbidity from malaria than 
their HIV-negative counterparts. 
 T able 2 
 Cost-effectiveness of ITN distribution (base-case results and results for simulated distribution schemes)* 
Scenario Deaths† averted LYs saved DALYs averted
Incremental cost-effectiveness ratio
$/Death averted $/LY $/DALY
Base-case 414 10,855 9,897 411.13 15.70 17.22
Distribution to women in
First or second pregnancy only 247 6,519 5,944 417.08 15.81 17.34
First–fourth pregnancy only 396 10,380 9,464 369.11 14.07 15.43
 * All costs are in 2005 US $. ITN = insecticide-treated bed net; LY = life year; DALY = disability-adjusted life-year. 
 †  Infant deaths only. 
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 We found that this program is the most cost-effective for 
women of lower parity (who with their infants are at greater 
risk of malaria sequelae), whereas benefits were lower for 
those women carrying their fifth or greater pregnancy. This 
phenomenon may be explained by the lack of effect of ITNs 
in reducing stillbirths and LBW deliveries after the fourth 
pregnancy. 1 In this case, the benefits are primarily to the infant 
who sleeps under the ITN during the first year of life. Under 
extremely resource-constricted circumstances, when perhaps 
it may be conceivable to prioritize distribution of ITNs to 
women in their first through fourth pregnancies or even to 
women in their first or second pregnancies, the intervention 
remains cost-effective. 
 We believe our analysis is conservative because we account 
only for infant mortality and do not account for the cost sav-
ings associated with a reduction in LBW deliveries or malaria 
cases averted in mothers or infants. For example, we do not 
account for health care use that would results from LBW or 
 F igure 1.  Incremental cost-effectiveness plane showing Monte Carlo estimates of incremental costs and effectiveness for adding insecticide-
treated bed net (ITN) distribution to routine care in antenatal clinics in Kinshasa, Democratic Republic of the Congo (DRC). Dashed line represents 
a threshold incremental cost-effectiveness ratio of US $15, the per capita healthcare expenditure in the DRC. Points to the right of and below the 
threshold indicate that adding ITNs is cost-effective if the decision maker is willing to pay that amount per disability-adjusted life year (DALY). 
 F igure 2.  Cost-effectiveness acceptability curve depicting the probability that adding insecticide-treated bed net (ITN) distribution to antenatal 
clinics is cost-effective at alternative decision-making thresholds. The dashed line indicates the likelihood that adding ITNs is optimal if one is will-
ing to pay US $15/disability-adjusted life year (DALY) (i.e., no more than the per capita health expenditures). 
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its sequelae. Also, we do not account for costs saved because 
of fewer medications used and less frequent clinic visits and 
hospitalizations for malaria. Currently in the DRC, 68% of 
outpatient visits and 30% of hospitalizations are estimated to 
be caused by malaria. 40 Because ITN use by children reduces 
rates of uncomplicated malaria by 50% and severe malaria by 
45%, 2 the cost-savings from decreased use of health services 
and medications is likely to be substantial. 
 A limitation of the study is that it simulates results for a sin-
gle region, an urban environment, in the DRC. In particular, 
we measured ITN adherence at one typical clinic in Kinshasa, 
rather than in all 28 clinics involved in the original ITN distri-
bution program. Thus, the observed adherence may be gen-
eralizable to many clinics in the capital, but may not reflect 
adherence in rural areas or in other urban areas in the DRC. 
To address this limitation, we use and describe sensitivity anal-
yses, which may permit wider applicability of our results. We 
also were unable to directly measure health outcomes (i.e., 
stillbirths, LBW deliveries, and vertical HIV transmission) 
for the women who received ITNs from our program. Instead 
we used outcomes data from the peer-reviewed literature 
and used sensitivity analysis to evaluate the effect of using 
these alternative data. Finally, we assumed that adherence 
with ITN use would stay the same from 6 months postpar-
tum, when it was measured, until 12 months postpartum, the 
end of our time frame for outcomes. Although ITN use may 
decrease over time, Lindblade and others 3 reported that ITN 
use increased during the course of the study, possibly because 
ITN use became more culturally acceptable. 
 The adherence with ITN use by the mothers and their 
infants in our study was somewhat higher than reported in the 
recent literature. Yukich and others 41 reported ITN use in chil-
dren less than five years of age ranging from 13.9% to 56% 
compared with 85% reported by mothers in our study at deliv-
ery. Had we used these lower rates, our incremental cost-effec-
tiveness ratios would have been US $18 to US $22 per DALY 
and US $424 to US $523 per death averted. However, distribu-
tion of ITNs in antenatal clinics has been associated with high 
adherence rates in other studies. 42 
 This analysis provides information that may be useful for 
governments and funding agencies that are considering add-
ing antenatal malaria prevention programs to existing antena-
tal services in sub-Saharan Africa. The results provide further 
support for the trend towards bundling preventive services 
to reduce overhead costs and reach the highest numbers of 
persons. 
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